Signed in as:
filler@godaddy.com
Ovarian Cancer Stemness and Chemoresistance
This webinar will delve into the latest research on AR's involvement in ovarian cancer, exploring its implications for diagnosis, treatment, and potential therapeutic strategies.
Chat with Dr. Makedonskaia: Your Expert Advisor. Chat button in the bottom right corner.
Session 1: Androgen Receptor Biology in Ovarian Cancer
Explore the fundamental biology of androgen receptor (AR) in ovarian cancer, including its expression, localization, and function. Dive into the complex signaling pathways mediated by androgen receptor in ovarian cancer. Discuss the latest advances in targeting androgen receptor for ovarian cancer therapy. Join our expert speakers as they provide insights into the critical role of androgen receptor in ovarian cancer and explore potential therapeutic strategies to improve patient outcomes.
Date: December 4, 2024
Time: 5:00 PM (on-line)
https://us05web.zoom.us/j/82241135869?pwd=BoCeD8NxL7jlEJs8BmBK3Mix5DoAbb.1
Join us for a conference where we will discuss the latest advancements in ovarian cancer treatment. Oncology experts will share their knowledge and experience in combating this disease. This conference marks the beginning of an exciting series, which will continue in a week, delving deeper into discussions and introducing new approaches to treatment. Don't miss the opportunity to learn about the most relevant research and methods that can change your practice!
Session 2: AR-Mediated Signaling Pathways in Ovarian Cancer
Androgen receptor (AR)-mediated signaling pathways play a significant role in the progression and treatment of ovarian cancer, particularly epithelial ovarian carcinoma (EOC). AR, a member of the nuclear receptor superfamily, is implicated in various cellular processes such as proliferation, migration, invasion, and stemness of cancer cells. Despite the potential therapeutic implications, clinical trials with anti-androgens have not shown significant results, although experimental studies suggest that targeting AR could suppress disease progression. This highlights the complexity and potential of AR-mediated pathways in ovarian cancer treatment strategies.
Date: December 11, 2024
Time: 5:00 PM (on-line)
This meeting is a continuation of our previous conference, and we invite doctors and oncology specialists to deepen their knowledge and share their experience in combating this disease. Experts will share new approaches and methods that can significantly improve treatment outcomes.
Don't miss the opportunity to learn about the latest trends and ask questions to leading experts!
Session 3: Therapeutic Targeting of AR in Ovarian Cancer
The androgen receptor (AR) signaling pathway is emerging as a potential therapeutic target in ovarian cancer, a disease characterized by high mortality and resistance to conventional treatments. AR-mediated signaling is implicated in the progression and survival of ovarian cancer cells, making it a promising focus for targeted therapy. Recent studies have explored the role of AR in ovarian cancer and the potential benefits of targeting this pathway to improve patient outcomes. Below, we delve into the key aspects of AR-mediated signaling pathways and their therapeutic targeting in ovarian cancer.
Date: December 18, 2024
Time: 5:00 PM (on-line)
You are cordially invited to join our upcoming conference, where we will delve into the latest research on the androgen receptor (AR) signaling pathway as a potential therapeutic target in ovarian cancer.Experts in the field will share their insights on:
- The role of AR-mediated signaling in ovarian cancer progression and survival
- The potential benefits of targeting the AR pathway to improve patient outcomes
- Recent studies and breakthroughs in AR-targeted therapy for ovarian cancer
Don't miss this opportunity to learn from leading experts and stay up-to-date on the latest advancements in ovarian cancer treatment. We look forward to seeing you there!
Q&A and Discussion.
Audience:
• Oncologists
• Gynecologists
• Cancer researchers
• Pharmacologists
• Scientists interested in ovarian cancer and cancer stemness